AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) recently revealed that its corporate position is reinforced in a strong foundation. In the recent past, AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that as of November 24, 2015, there wasn’t any specific corporate development that changed the position of the company in the stock exchange. However, it must be noted, that recently, the company also made another crucial announcement. Some of the major highlights of its announcements are as follows.
Recent Developments in AEterna Zentaris Inc. (USA)
The company’s much-acknowledged drug, Zoptrex™ (zoptarelin doxorubicin) received a green signal from DSMB recommendation so as to carry on with its ZoptEC Phase 3 clinical programme. In its third phase of the clinical programme, the company shall review safety data along with the final interim efficiency of the drug. In fact, the company also received the confirmed participation of its first patient.
If the third phase of the clinical research goes well, AEterna will have a breakthrough in men’s health. Also, it will reinforce the position of the company in the Pharma market.
Zoptrex™ has already reached Phase 2 clinical programme’s milestone. AEterna through this drug has been able to prove that it is beneficial for the treatment of those men who have experienced issues like prostate cancer or pre-treated castration.
Strong cash flow through effective drug sales
Apart from the clinical research regarding its important drug, Aeterna Zentaris Inc. (USA) (NASDAQ:AEZS) explains that the sales of its drugs, viz. EstroGel® and Saizen® are showing positive signs.
The company is also managing its cash flow through dilution by seeking the Series B Shares. As far as the cash flow surrounding its Series B shares is concerned, the company has already revealed that even though there has been an overhaul in the company; but the price of shares is reeling under immense pressure.